A Turning Point in Psychedelic Medicine
In a groundbreaking move, the US Food and Drug Administration (FDA) publicly released a Complete Response Letter (CRL) to Lykos Pharmaceuticals, explaining its decision to decline approval of MDMA-assisted therapy for PTSD. This marks the first time the FDA has shared such letters with the public, along with 89 previously unpublished CRLs, in an effort to make its drug approval process more transparent.
For many in the mental health field, this decision represents more than just a setback for one treatment. It opens a larger conversation about how psychedelic-assisted therapies will be evaluated, regulated, and eventually integrated into psychiatric care.
What Is MDMA-Assisted Therapy for PTSD?
MDMA-assisted therapy combines the psychoactive drug MDMA with structured psychotherapy sessions. Research has shown promising results for patients with treatment-resistant PTSD, who often struggle to find relief with standard medications and talk therapy. Advocates see it as a potentially life-changing tool that could reshape trauma care worldwide.
However, designing clinical trials for psychedelic therapies is notoriously complex. Unlike traditional medications, the therapeutic effect is closely tied to the psychotherapy environment, patient expectations, and unique subjective experiences. This makes creating blinded, placebo-controlled studies far more challenging.
Why the FDA Said No
The FDA’s CRL pointed to several issues with Lykos’s submission. The agency expressed concern about study design, including the lack of a low-dose comparison arm and the durability of treatment benefits over time. It also noted the potential impact of participants’ prior MDMA use, though data from the trials showed little difference between those who had previously used the drug and those who had not.
What frustrated many researchers was that these concerns appeared inconsistent with earlier FDA guidance. According to Rick Doblin, PhD, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS), the FDA had originally advised against using a low-dose control group, only to later cite its absence as a shortcoming. Critics argue that this shifting of standards creates uncertainty and slows down the development of innovative therapies.
The Response from MAPS
MAPS, which has spent decades supporting MDMA research, expressed disappointment but also determination. In a statement, the organization emphasized that it will continue training therapists, supporting humanitarian projects in high-trauma regions, and pushing forward new studies.
Doblin highlighted that the CRL overlooked amendments Lykos had already submitted to address earlier concerns. He argued that while regulatory caution is expected, moving the “goalposts” undermines collaboration and delays access to treatments that could help patients with severe trauma.
Looking Ahead
While the FDA’s decision was a setback, the release of CRLs is an important step toward transparency in mental health drug approvals. Clinicians, researchers, and patients now have direct access to the reasoning behind rejections, which could guide future studies and improve collaboration between sponsors and regulators.
The future of MDMA-assisted therapy for PTSD remains uncertain. Lykos is expected to continue negotiations with the FDA, while MAPS and other organizations push ahead with research worldwide. Regardless of the outcome, this moment represents a turning point in the conversation about psychedelic-assisted therapies—balancing innovation, safety, and regulatory trust.
References
- MAPS — MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy (September 4, 2025). MAPS. Available at: https://maps.org/2025/09/04/fda-public-release-of-crl/
- FDA announces real-time release of complete response letters, posts previously unpublished batch of 89. US Food and Drug Administration. September 4, 2025. Accessed September 5, 2025. https://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89